Who are Lantheus Holdings, Inc.'s main suppliers?

Lantheus Holdings, Inc. (LNTH) key suppliers include: PMF-NETWORKS, POINT, AC Immune SA, AC Immune SA, Perspective Therapeutics, Inc. and 11 more. View the full supplier network at chainsifter.com/chain/LNTH.

Who are Lantheus Holdings, Inc.'s major customers?

Lantheus Holdings, Inc. (LNTH) key customers include: AC Immune SA, AC Immune SA, Perspective Therapeutics, Inc., Perspective Therapeutics, Inc., LTGHY and 25 more. View the full customer network at chainsifter.com/chain/LNTH.

What sector is Lantheus Holdings, Inc. in?

Lantheus Holdings, Inc. (LNTH) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Lantheus Holdings, Inc. Supplier List (LNTH): 16 Verified Suppliers

16Suppliers

30Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Lantheus Holdings, Inc. (LNTH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

61Total relationships

3Distinct source URLs

4High confidence

0.690Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Lantheus Holdings, Inc. Suppliers

Ticker	Name	Confidence	Evidence
PMF-NETWORKS	PMF-NETWORKS	92%	Our agreements with our PMF networks allow for termination upon the occurrence of specified events, including material breach or bankruptcy by either party
POINT	POINT	92%	we are also currently dependent on POINT to develop commercial product capacity and manufacture for both PNT2003 and PNT2002
ACIU	AC Immune SA	72%	Reciprocal relationship from ACIU graph: Reciprocal relationship from LNTH graph: Item 1A. “Risk Factors” of this Form 10-K for information regarding certain risks associated with our raw materials a…
ACIU	AC Immune SA	72%	Item 1A. “Risk Factors” of this Form 10-K for information regarding certain risks associated with our raw materials and supply arrangements. Manufacturing The commercial manufacture of PYLARIFY and N…
CATX	Perspective Therapeutics, Inc.	72%	Reciprocal relationship from CATX graph: Reciprocal relationship from LNTH graph: tion and the potential that efforts to extend or secure separate or otherwise adequate payment for radiopharmaceutica…
CATX	Perspective Therapeutics, Inc.	72%	tion and the potential that efforts to extend or secure separate or otherwise adequate payment for radiopharmaceutical diagnostics are unsuccessful. • The extensive government regulation and oversigh…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from LNTH graph: ources, raw materials and, for our diagnostic imaging agents, staff at imaging centers and hospitals and PET scanner…
NVSEF	Novartis AG	72%	ources, raw materials and, for our diagnostic imaging agents, staff at imaging centers and hospitals and PET scanner capacity. For example, for PNT2003, our principal competitors may include Novartis…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from LNTH graph: g degrees of governmental regulation in the countries in which we or our partners operate, and the general trend is …
ORANY	ORANY	72%	g degrees of governmental regulation in the countries in which we or our partners operate, and the general trend is toward increasingly stringent regulation. To assess and facilitate compliance with …
RADX	Radiopharm Theranostics Limited	72%	tion and the potential that efforts to extend or secure separate or otherwise adequate payment for radiopharmaceutical diagnostics are unsuccessful. • The extensive government regulation and oversigh…
RADX	Radiopharm Theranostics Limited	72%	Reciprocal relationship from RADX graph: Reciprocal relationship from LNTH graph: tion and the potential that efforts to extend or secure separate or otherwise adequate payment for radiopharmaceutica…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from LNTH graph: Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Pe…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2025 and 2024 - Revenues” for further information on reve…
TLX	Telix Pharmaceuticals Limited	72%	Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in o…
TLX	Telix Pharmaceuticals Limited	72%	ial financial, manufacturing, sales and marketing, distribution and other resources. • For PYLARIFY, our principal competitors are currently Telix Pharmaceuticals Limited, Blue Earth Diagnostics Ltd.…

Lantheus Holdings, Inc. Customers

Ticker	Name	Confidence	Evidence
ACIU	AC Immune SA	72%	Item 1A. “Risk Factors” of this Form 10-K for information regarding certain risks associated with our raw materials and supply arrangements. Manufacturing The commercial manufacture of PYLARIFY and N…
ACIU	AC Immune SA	72%	Reciprocal relationship from ACIU graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from ACIU g…
CATX	Perspective Therapeutics, Inc.	72%	Reciprocal relationship from CATX graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from CATX graph: Reciprocal relationship from LNTH graph: ble for the performance of certain …
CATX	Perspective Therapeutics, Inc.	72%	ble for the performance of certain key tasks or functions, for example related to manufacturing or regulatory strategy, or where decisions may be controlled by, or subject to the approval of our coll…
LTGHY	LTGHY	72%	Reciprocal relationship from LTGHY graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from LTGHY graph: Reciprocal relationship from LNTH graph: . The Company incurred $ 28.0 mil…
LTGHY	LTGHY	72%	. The Company incurred $ 28.0 million of acquisition- and integration-related costs in 2025. These costs were recorded in operating expenses in the condensed consolidated statements of operations in …
MNPR	Monopar Therapeutics Inc.	72%	Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities …
NVSEF	Novartis AG	72%	ncreasingly competitive environment in which other PSMA PET imaging agents have been approved, for which discounts related to those other agents have been offered to customers and for which TPT Statu…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LNTH graph: ncreasingly competitive environme…
ORANY	ORANY	72%	hod-of-use patents listed in the FDA’s publication, ”Approved Drug Products with Therapeutic Equivalence Evaluations” (the “Orange Book”), as well as additional manufacturing patents that are not Ora…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from ORAN…
RADX	Radiopharm Theranostics Limited	72%	ble for the performance of certain key tasks or functions, for example related to manufacturing or regulatory strategy, or where decisions may be controlled by, or subject to the approval of our coll…
RADX	Radiopharm Theranostics Limited	72%	Reciprocal relationship from RADX graph: Reciprocal relationship from LNTH graph: ble for the performance of certain key tasks or functions, for example related to manufacturing or regulatory strateg…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LNTH graph: Item 7. “Management’s Discussion an…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2025 and 2024 - Revenues” for further information on reve…
TLX	Telix Pharmaceuticals Limited	72%	ncreasingly competitive environment in which other PSMA PET imaging agents have been approved, for which discounts related to those other agents have been offered to customers and for which TPT Statu…
TLX	Telix Pharmaceuticals Limited	72%	Reciprocal relationship from TLX graph: Reciprocal relationship from LNTH graph: ncreasingly competitive environment in which other PSMA PET imaging agents have been approved, for which discounts rel…
ACP-LANTERN-CO-INVEST-LLC	ACP-LANTERN-CO-INVEST-LLC	62%	RG and the Lantheus Veterans, Employees and Reservists Inspired to Act and Serve ERG. We are committed to promoting a culture of ethics and compliance. Our Code of Conduct and Ethics reflects our com…
BLUE-EARTH-DIAGNOSTICS-LTD	BLUE-EARTH-DIAGNOSTICS-LTD	62%	mote PYLARIFY to customers, to clinically and commercially differentiate PYLARIFY from other products on the market and to maintain PYLARIFY as the most utilized PSMA PET imaging agent in a competiti…
BRACCO-DIAGNOSTICS-INC	BRACCO-DIAGNOSTICS-INC	62%	that we serve. Any delay or inability to enter into these arrangements, including our ability to negotiate favorable financial terms in these agreements, or if, despite favorable financial terms, the…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	in excess tax benefits associated with our payment of stock-based compensation. Liquidity and Capital Resources Cash Flows The following table provides information regarding our cash flows: Three Mon…
CERVEAU-TECHNOLOGIES-INC	CERVEAU-TECHNOLOGIES-INC	62%	ailability of PET scanners could impact our ability to grow PYLARIFY and to successfully launch and commercialize radiodiagnostic products in our pipeline. Use of our radiopharmaceutical diagnostic p…
EVERGREEN-THERAGNOSTICS-INC	EVERGREEN-THERAGNOSTICS-INC	62%	ailability of PET scanners could impact our ability to grow PYLARIFY and to successfully launch and commercialize radiodiagnostic products in our pipeline. Use of our radiopharmaceutical diagnostic p…
GE-HEALTHCARE-LIMITED	GE-HEALTHCARE-LIMITED	62%	that we serve. Any delay or inability to enter into these arrangements, including our ability to negotiate favorable financial terms in these agreements, or if, despite favorable financial terms, the…
ILLUMINATED-HOLDINGS-INC	ILLUMINATED-HOLDINGS-INC	62%	eporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date.” ASU 2024-03 requires additional income statement disclosures, including the disag…
LANTHEUS-BIOSCIENCES-LTD	LANTHEUS-BIOSCIENCES-LTD	62%	. The Company incurred $ 28.0 million of acquisition- and integration-related costs in 2025. These costs were recorded in operating expenses in the condensed consolidated statements of operations in …
LANTHEUS-HOLDINGS	LANTHEUS-HOLDINGS	62%	nt Balance at January 1, 2026 $ 239,517 Foreign currency translation adjustments ( 118 ) Balance at March 31, 2026 $ 239,399 17 Table of Contents Lantheus Holdings, Inc. Notes to Condensed Consolidat…
LANTHEUS-MEDICAL-LANTHEUS-HOLDINGS	LANTHEUS-MEDICAL-LANTHEUS-HOLDINGS	62%	nt Balance at January 1, 2026 $ 239,517 Foreign currency translation adjustments ( 118 ) Balance at March 31, 2026 $ 239,399 17 Table of Contents Lantheus Holdings, Inc. Notes to Condensed Consolidat…
LANTHEUS-MEDICAL-LANTHEUS-MI-CANADA-INC-LANTHEUS	LANTHEUS-MEDICAL-LANTHEUS-MI-CANADA-INC-LANTHEUS	62%	n March 6, 2026, we announced that the FDA approved PYLARIFY TruVu (piflufolastat F18), a new formulation of our F-18 PSMA PET imaging agent. PYLARIFY TruVu is indicated for PET imaging of PSMA-posit…
LDCP-PERSPECTIVE-THERAPEUTICS-INC	LDCP-PERSPECTIVE-THERAPEUTICS-INC	62%	es and other current liabilities in the Company’s consolidated balance sheets. These rebates result from performance-based offers that are primarily based on attaining contractually specified sales v…

Lantheus Holdings, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
LNTH-DEBT	Debt stack $558.4M	90%	Market cache reports total debt of $558.4M.

Lantheus Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lantheus Holdings, Inc..

Lantheus Holdings, Inc. Ownership

Holder	Name	Confidence	Evidence
LNTH-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 411 tracked holders.

Lantheus Holdings, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
ACET	Adicet Bio, Inc.	100.00	2
CLRB	Cellectar Biosciences, Inc.	100.00	2
SLGL	Sol-Gel Technologies Ltd.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
ABT	Abbott Laboratories	100.00	2
ATNM	Actinium Pharmaceuticals, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
BSX	Boston Scientific Corporation	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
CATX	Perspective Therapeutics, Inc.	100.00	1	['customer', 'supplier']
BIOA	BioAge Labs, Inc.	100.00	2
ARTV	Artiva Biotherapeutics, Inc.	100.00	2

Lantheus Holdings, Inc. Supply Chain